We stay current on NIH happenings and would be delighted to keep you informed.
The end of the COVID Public Health Emergency on May 11, 2023 will bring changes to NIH, AHRQ, and NIOSH guidance implemented during the pandemic. Effective for applications submitted on May 25, 2023 and beyond, a one-page update of preliminary data as post-submission material may be submitted only for R01, R03, and R21 applications, as long as the funding opportunity allows submission of preliminary data. The Notice is available here: https://bit.ly/3ZP9no4
Margaret Bouvier received her PhD in 1995 in Biomedical Sciences from the Mount Sinai School of Medicine. After an NINDS post-doctoral fellowship, she worked as a staff writer for long-standing NIH Director Dr. Francis Collins in the Office of Press, Policy, and Communications for the Human Genome Project and NHGRI. Since 2007, Meg has specialized in editing and advising on NIH submissions, and began offering virtual courses in 2015. She's recently worked with more than 40% of the nation's highest-performing hospitals*, four of the top 10 cancer hospitals, three of the top five medical schools for research, and 14 NCI-designated cancer centers. Her experience at NIH as both a bench scientist and staff writer greatly informs her approach to NIH grantwriting. She has helped clients land over half a billion in federal funding. Bouvier Grant Group is a woman-owned small business.
*Our clients include 9 of the top 22 hospitals as recognized by the 2023/24 US News & World Report honor roll
